gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatment.

SOCS gene expression at diagnosis has been suggested as a predictor of clinical outcome in chronic myeloid leukemia (CML). In this study and expression levels were determined by real-time PCR in pretherapeutic samples at diagnosis. First, three patient groups were compared after assessment at 48 months: optimal molecular responders ( = 35), patients with resistance to imatinib ( = 28), and blast crisis patients ( = 27).